A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer

doi:10.1007/s00259-022-05701-3

CORC > 自动化研究所 > 中国科学院自动化研究所 > 中国科学院分子影像重点实验室

	A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer
	Shang, Wenting 2; Peng, Li 1,4; He, Kunshan 2,3; Guo, Pengyu 1,4; Deng, Han 2; Liu, Yu 3; Chen, Ziyin 1,4; Tian, Jie 2,3; Xu, Wanhai 1,4
刊名	EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
	2022-02-21
页码	13
关键词	Bladder cancer Near-infrared imaging Peptide Diagnosis Endoscopy
ISSN号	1619-7070
DOI	10.1007/s00259-022-05701-3
通讯作者	Tian, Jie(jie.tian@ia.ac.cn) ; Xu, Wanhai(xuwanhai@163.com)
英文摘要	Background Bladder cancer is the fifth most common malignancy in humans. Cystoscopy under white light imaging is the gold standard for bladder cancer diagnosis, but some tumors are difficult to visualize and can be overlooked, resulting in high recurrence rates. We previously developed a phage display-derived peptide-based near-infrared imaging probe, PLSWT7-DMI, which binds specifically to bladder cancer cells and is nontoxic to animals. Here, we report a clinical research of this probe for near-infrared fluorescence endoscopic detection of bladder cancer. Results The purity, efficacy, safety, and nontoxicity of PLSWT7-DMI were confirmed prior to its clinical application. Twenty-two patients diagnosed with suspected non-muscle invasive bladder cancer were enrolled in the present study. Following intravesical administration of the probe, the entire mucosa was imaged under white and near-infrared imaging using an in-house developed endoscope that could switch between these two modes. The illuminated lesions under near-infrared light were biopsied and sent for histopathological examination. We observed a 5.1-fold increase in the fluorescence intensity in the tumor samples compared to normal tissue, and the probe demonstrated a sensitivity and specificity of 91.2% and 90%, respectively. Common diagnostic challenges, such as small satellite tumors, carcinoma in situ, and benign suspicious mucosa, were visualized and could be distinguished from cancer. Furthermore, no adverse effects were observed in humans. These first-in-human results indicate that PLSWT7-DMI-based near-infrared fluorescence endoscopy is a safe and effective approach for the improved detection of bladder cancer, and may enable thorough resection to prevent recurrence.
WOS关键词	CARCINOMA IN-SITU ; TRANSURETHRAL RESECTION ; PHOTODYNAMIC DIAGNOSIS ; LIGHT CYSTOSCOPY ; WHITE-LIGHT ; RECURRENCE ; THERAPY
WOS研究方向	Radiology, Nuclear Medicine & Medical Imaging
语种	英语
出版者	SPRINGER
WOS记录号	WOS:000758972300001
内容类型	期刊论文
源URL	[http://ir.ia.ac.cn/handle/173211/47882]
专题	自动化研究所_中国科学院分子影像重点实验室
通讯作者	Tian, Jie; Xu, Wanhai
作者单位	1.Harbin Med Univ, Urol Surg Dept, Hosp 4, Harbin 150001, Heilongjiang, Peoples R China 2.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing Key Lab Mol Imaging,State Key Lab Managem, Beijing 100190, Peoples R China 3.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Sch Med & Engn, Zhongguancun East Rd 95, Beijing 100191, Peoples R China 4.NHC Key Lab Mol Probes & Targeted Diag & Therapy, Yiyuan St 37, Harbin 150001, Heilongjiang, Peoples R China
推荐引用方式 GB/T 7714	Shang, Wenting,Peng, Li,He, Kunshan,et al. A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,2022:13.
APA	Shang, Wenting.,Peng, Li.,He, Kunshan.,Guo, Pengyu.,Deng, Han.,...&Xu, Wanhai.(2022).A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,13.
MLA	Shang, Wenting,et al."A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer".EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022):13.